Denileukin diftitox: all 39 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell LymphomaCompletedNCT02676778Phase 2Results posted
• A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell LymphomaCompletedNCT01871727Phase 3Results posted
• E7777 for the Treatment of Patients With Peripheral T-Cell LymphomaCompletedNCT01401530Phase 1Results posted
• Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous TransplantationTerminatedNCT01251952Phase 1Results posted
• Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV MelanomaCompletedNCT01127451Phase 2Results posted
• A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian CancerCompletedNCT00880360Phase 2Results posted
• A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic CancerTerminatedNCT00726037Phase 2Results posted
• Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)TerminatedNCT00632827Phase 2Results posted
• Vaccination Plus Ontak in Patients With Metastatic MelanomaTerminatedNCT00515528Phase 2Results posted
• Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's LymphomaCompletedNCT00460109Phase 2Results posted
• ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous TreatmentCompletedNCT00425672Phase 1/2Results posted
• A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell LymphomaCompletedNCT00337987Phase 2Results posted
• Phase II Trial of Ontak With Metastatic MelanomaCompletedNCT00299689Phase 2Results posted
• Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)CompletedNCT00224874Phase 2Results posted
• A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell LymphomaCompletedNCT00211185Phase 2Results posted
• Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell LeukemiaTerminatedNCT00117845Phase 2Results posted
• Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)CompletedNCT00051025Phase 2Results posted
• T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid TumorsActive, not recruitingNCT05200559Phase 1/2
• Ph I/II Study of E7777 Prior to CAR-T for R/R LBCLSuspendedNCT04855253Phase 1/2
• A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell LymphomaWithdrawnNCT01355783Phase 3
• Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV MelanomaTerminatedNCT00945269Phase 1/2
• Denileukine Diftitox for Relapsed ALCLWithdrawnNCT00801918Phase 2
• Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin LymphomaWithdrawnNCT00513188Not applicable
• Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)CompletedNCT00493129Phase 2
• Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube CancerCompletedNCT00357448Phase 1
• Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal CancerCompletedNCT00278369Early Phase 1
• Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu VaccineCompletedNCT00228358Phase 1
• A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's LymphomaCompletedNCT00211276Phase 2
• Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)CompletedNCT00211198Phase 4
• Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00138164Phase 2
• Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic CancerCompletedNCT00128622Phase 1
• Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic LeukemiaCompletedNCT00082940Phase 2
• Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney CancerCompletedNCT00082914Phase 2
• Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)CompletedNCT00055146Phase 2
• Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma PatientsCompletedNCT00051012Phase 4
• Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) PatientsCompletedNCT00050999Phase 4
• Denileukin Diftitox in Treating Patients With Non-Hodgkin's LymphomaStatus unknownNCT00026429Phase 2
• Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell LymphomaCompletedNCT00006345Phase 2
• Denileukin Diftitox in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00003615Phase 2

← Denileukin diftitox overview